[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinical Sciences
December 2006

Longitudinal Postnatal Weight and Insulin-like Growth Factor I Measurements in the Prediction of Retinopathy of Prematurity

Author Affiliations

Author Affiliations: Göteborg Pediatric Growth Research Center, Department of Pediatrics, Institute of the Health of Women and Children (Drs Löfqvist, Sigurdsson, Engström, Niklasson, and Hellström), Statistical Research Unit (Dr Andersson), and Department of Ophthalmology, Institute of Clinical Neuroscience (Drs Hård and Hellström), Göteborg University, Göteborg, Sweden; and Department of Ophthalmology, Children's Hospital, Harvard Medical School, Boston, Mass (Drs Löfqvist and Smith).

Arch Ophthalmol. 2006;124(12):1711-1718. doi:10.1001/archopht.124.12.1711

Objective  To investigate whether postnatal growth and development influence retinopathy of prematurity (ROP) and may be included in screening for ROP.

Design  We developed an algorithm to predict for individual infants the risk of later ROP development requiring treatment based on the postnatal longitudinal systemic factors of insulin-like growth factor I (IGF-I) level, IGF binding protein 3 level, and postnatal weight gain. We developed the algorithm based on 79 preterm infants considered at risk for ROP by standard criteria (gestational age, 23.6-31.7 weeks) in a longitudinal study measuring weight gain and serum IGF-I and IGF binding protein 3 levels weekly from birth until discharge from the hospital. We monitored deviations from reference models for weight and IGF-I level (preterm children who developed no or minimal ROP) to detect indications for treatable ROP by Early Treatment for Retinopathy of Prematurity study criteria.

Results  This monitoring method detected 6 (100%) of 6 infants in this cohort who required treatment for ROP with a warning signal at least 5 weeks before requiring treatment and at least 3 weeks before the onset of stage 3 ROP. The majority of infants (61/73 infants) requiring no treatment were also correctly identified.

Conclusions  Monitoring the postnatal factors of weight, IGF-I level, and IGF binding protein 3 level substantially enhances the clinician's ability to identify patients who will require treatment for ROP.